SUPN Supernus Pharmaceuticals, Inc.

32.95
+1  (2%)
Previous Close 32.40
Open 32.60
Price To book 8.44
Market Cap 1.65B
Shares 50,162,000
Volume 457,355
Short Ratio 3.68
Av. Daily Volume 561,177

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approved October 22, 2017.
Oxtellar
Epilepsy
Phase 2b trial met primary endpoint - October 11, 2016. Phase 3 planned for 2H 2017.
SPN-812
ADHD
Phase 3 enrollment to continue through to 2017.
SPN-810
Impulsive Aggression in ADHD
Approved Aug 19, 2013.
Trokendi
Epilepsy
Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.
Trokendi
Migraine

Latest News

  1. Harry Boxer’s momentum stocks to watch: 3 biotechs, 1 retailer
  2. This Biotech Leader Breaks Out, Defying Sector Odds
  3. Supernus Drug Gets Label Expansion for Migraines
  4. Supernus Receives Final FDA Approval for Trokendi XR® for Migraine Prophylaxis in Adults and Adolescents
  5. 3 Highest Growth Stocks in the Market Today
  6. Ultragenyxs’ Seizure Drug Fails Study
  7. Supernus Pharma Tanks on Settlement of Two Patent Disputes (SUPN)
  8. These Pharma Stocks Are Big Losers From Trump's Drug-Pricing Tweet
  9. Supernus Announces Settlement with Actavis on Trokendi XR® Patent Litigation
  10. Supernus Announces Settlement with Zydus on Trokendi XR® Patent Litigation
  11. ETFs with exposure to Supernus Pharmaceuticals, Inc. : March 6, 2017
  12. Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017
  13. Edited Transcript of SUPN earnings conference call or presentation 1-Mar-17 2:00pm GMT
  14. Supernus tops Street 4Q forecasts
  15. Supernus Announces Record Fourth Quarter and Full Year 2016 Financial Results
  16. Supernus to Present at Cowen Health Care Conference in March
  17. Will Mylan, Glaukos, Supernus Live Up To Q4 Growth Views Next Week?
  18. Supernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call
  19. Supernus Announces Issuance of Eighth U.S. Patent Protecting Trokendi XR®
  20. Top 4 Pharmaceutical Stocks for 2017

SEC Filings

  1. 8-K - Current report 17756378
  2. 10-K - Annual report (Section 13 and 15(d), not S-K Item 405) 17694715
  3. 8-K - Current report 17679132
  4. 8-K - Current report 17675630
  5. NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 17655179
  6. 8-K - Current report 17651104
  7. S-8 - Securities to be offered to employees in employee benefit plans 17622295
  8. 8-K - Current report 17615209
  9. 8-K - Current report 17593914
  10. 8-K - Current report 17565526